ImmuCell Corporation

11/07/2025 | Press release | Distributed by Public on 11/07/2025 06:41

Initial Statement of Beneficial Ownership (Form 3)

FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
te Boekhorst Paul Francis Olivier
2. Date of Event Requiring Statement (Month/Day/Year)
10/29/2025
3. Issuer Name and Ticker or Trading Symbol
IMMUCELL CORP /DE/ [ICCC]
(Last) (First) (Middle)
C/O IMMUCELL CORPORATION, 56 EVERGREEN DRIVE
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
President and CEO
5. If Amendment, Date Original Filed (Month/Day/Year)
(Street)
PORTLAND, ME 04103
6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Non Qualified Stock Option (right to buy) 09/16/2026 09/16/2035 Common Stock 25,327 $5.9 D
Non Qualified Stock Option (right to buy) 09/16/2027 09/16/2035 Common Stock 25,327 $5.9 D
Non Qualified Stock Option (right to buy) 09/16/2028 09/16/2035 Common Stock 25,329 $5.9 D

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
te Boekhorst Paul Francis Olivier
C/O IMMUCELL CORPORATION
56 EVERGREEN DRIVE
PORTLAND, ME 04103
X President and CEO

Signatures

/s/ Timothy C. Fiori Attorney-in-Fact 11/07/2025
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Remarks:
Option grant made to Mr. te Boekhorst at the time he and the Issuer entered into an offer letter outlining the tentative terms of his employment as President and CEO. Option granted as a nonqualified stock option within the meaning of the Internal Revenue Code. Option vests in 3 increments as shown in the foregoing table.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
ImmuCell Corporation published this content on November 07, 2025, and is solely responsible for the information contained herein. Distributed via Edgar on November 07, 2025 at 12:41 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]